Browse

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

DC Field Value Language
dc.contributor.authorVan Cutsem, Eric-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorFeng-Yi, Feng-
dc.contributor.authorXu, Jian M.-
dc.contributor.authorLee, Keun-Wook-
dc.contributor.authorJiao, Shun-Chang-
dc.contributor.authorChong, Jorge Leon-
dc.contributor.authorLopez-Sanchez, Roberto I.-
dc.contributor.authorPrice, Timothy-
dc.contributor.authorGladkov, Oleg-
dc.contributor.authorStoss, Oliver-
dc.contributor.authorHill, Julie-
dc.contributor.authorNg, Vivian-
dc.contributor.authorLehle, Michaela-
dc.contributor.authorThomas, Marlene-
dc.contributor.authorKiermaier, Astrid-
dc.contributor.authorRueschoff, Josef-
dc.date.accessioned2021-01-31T11:10:11Z-
dc.date.available2021-01-31T11:10:11Z-
dc.date.issued2015-07-
dc.identifier.citationGastric Cancer, Vol.18 No.3, pp.476-484-
dc.identifier.issn1436-3291-
dc.identifier.other61662-
dc.identifier.urihttps://hdl.handle.net/10371/173075-
dc.description.abstractIn the Trastuzumab for GAstric cancer (ToGA) study, trastuzumab plus chemotherapy improved median overall survival by 2.7 months in patients with human epidermal growth factor receptor 2 (HER2)-positive [immunohistochemistry (IHC) 3+/fluorescence in situ hybridization-positive] gastric/gastroesophageal junction cancer compared with chemotherapy alone (hazard ratio 0.74). Post hoc exploratory analyses in patients expressing higher HER2 levels (IHC 2+/fluorescence in situ hybridization-positive or IHC 3+) demonstrated a 4.2-month improvement in median overall survival with trastuzumab (hazard ratio 0.65). The ToGA study provides the largest screening dataset available on HER2 overexpression/amplification in this indication. We further analyzed correlation(s) of HER2 overexpression/amplification with clinical and epidemiological factors. HER2-positivity was analyzed by histological subtype, tumor location, geographic region, and specimen type. Exploratory efficacy analyses were performed. The HER2-positivity rate was 22.1 % across analyzed tumor samples. Rates were similar between European and Asian patients (23.6 % vs. 23.9 %), but higher in intestinal- vs. diffuse-type (31.8 % vs. 6.1 %), and gastroesophageal junction cancer versus gastric tumors (32.2 % vs. 21.4 %). Across all IHC scores, variability in HER2 staining (a parts per thousand currency sign30 % stained cells) was observed in almost 50 % of cases, with increasing rates in lower IHC categories, and did not affect treatment outcome. The polysomy rate was 4 %. HER2 expression varies by tumor location and type. All patients with advanced gastric or gastroesophageal junction cancer should be tested for HER2 status, preferably using IHC initially. Due to the unique characteristics of gastric cancer, specific testing/scoring guidelines should be adhered to.-
dc.subjectGastric cancer-
dc.subjectHER2 testing-
dc.subjectImmunohistochemistry-
dc.subjectIn situ hybridization-
dc.subjectTrastuzumab-
dc.titleHER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1007/s10120-014-0402-y-
dc.citation.journaltitleGastric Cancer-
dc.identifier.scopusid2-s2.0-84938973205-
dc.citation.endpage484-
dc.citation.number3-
dc.citation.startpage476-
dc.citation.volume18-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs10120-014-0402-y-
dc.identifier.rimsid61662-
dc.identifier.sci000358325000004-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse